RECEIVED

IN THE UNITED STATES PATENT AND TRADEMERK OFFICE

MAY 3 0 2002

In re Application of:

NERI et al.

TECH CENTER 1600/2900

Serial No.: 09/194,356

TECH CENTER 1600/2900 TECH CENTER 1600/2900

Filed: September 2, 1999

Examiner: 1642

PHOD

For: Antibodies to the ed-b domain of fibronectin, their construction and uses

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

CITED MATERIALS

	Appli	cant(s) hereby disclose the information listed in the attached form PTO-1449.
		Copies of materials listed but not attached were cited in parent application Serial No; see 37 C.F.R. § 1.98(d).
		Copies of materials listed but not attached were cited in an International Search Report dated; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed
	ADD:	ITIONAL INFORMATION
. 	[NON]	TE?]
1	LANC	GUAGE
	⊠	All listed materials are in the English language; see 37 C.F.R. § 1.98.
		Non-English language references:
÷		☐ The reference(s): in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): , respectively.
	,	☐ (An) English-language translation(s) of the references: is (are) provided.
06/04/2002 RHARMON	00000008 0	☐ A commercial English-language abstract of reference(s) is (are) provided.
01 FC:126		□ 180.00 All English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

<u>FEES</u>

	No fee	is required for this Information Disclosure Statement because:
	within	This Information Disclosure Statement is being filed within three months filing date of a national application (other than a CPA) under § 1.53(d) or 3 months of the date of entry of the national stage under § 1.491 in an tional application;
	□ a first a	This Information Disclosure Statement is being filed before the mailing of action on the merits;
	notice	This Information Disclosure Statement is being filed after a first action on rits but before the mailing date of any of a final action under § 1.113, a of allowance under § 1.311, or an action that closes prosecution in the ation, and is accompanied by a certification below.
		This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
×	A fee i	s required for this Information Disclosure Statement:
	notice	This Information Disclosure Statement is being filed after a first action on rits but before the mailing date of any of a final action under § 1.113, a of allowance under § 1.311 or an action that closes prosecution, and is panied by the fee set forth in §1.17(p).
	prosecu	This Information Disclosure Statement is being filed after the mailing date al rejection or a notice of allowance under § 1.311 or an action that closes ation, but before the payment of the issue fee, and is accompanied by the forth in § 1.17(p) and a certification below.
CERT	IFICAT	<u>ION</u>
-	cited in	em of information contained in this Information Disclosure Statement was a communication from a foreign patent office in a counterpart foreign tion not more than three months prior to the filing of this statement.
⊠	cited in applica inquiry	n of information contained in this Information Disclosure Statement was a communication from a foreign patent office in a counterpart foreign and, to the knowledge of the undersigned, having made reasonable, no such item was known to any individual designated in 37 CFR § , more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$180.00. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J/Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: NOTAR-2

Date: May 30, 2002

AJZ:jph K:\NOTAR 1 P1 (see also SCH 1733 P1)\Information Disclosure Statement053002.doc

Substitute for form 1449A/PTO



Approved for use through 10/31/2002. OMB 0651-0031

	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required	to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	L	Complete if Kn wn
	Application Number	0 9/194,356
INFORMATION DISCLOSURE	Filing Date	September 2, 199
STATEMENT BY APPLICANT	First Named Inventor	NERI et al.
	Group Art Unit	1642

(use as many sheets as necessary) Sheet of

Application Number	19 9/194,356	a		_
Filing Date	September 2, 1	9997		7
First Named Inventor	NERI et al.	呈	۷	11
Group Art Unit	1642	2	5	(,
Examiner Name	A. M. Harris	Z,		n
Attorney Docket Number	NOTAR-2	四	٠	7

					U.S. PATENT DOCU	MENTS	1500
		U.S. Pa	stent Docume	nt	Name of Patentee or Applicant	Date of Publication of	
Examiner Initials *	Cite No.1	Number	Kind Cod (if known)		Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Resevent Figures Appear
	 	ļ					
	 	 -					·
		 					
	ļ						
							
		 					
	ļ. <u></u>	ļ <u>.</u>					
		ļ					
		 					
				_ +			

				FOREIG	N PATENT DOCU	MENTS		
Examiner Cite No.1	Fore	eign Patent D	ocument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	Office ³	Number ⁴	Kind Code ⁵ (if known)				T ₆	
		ļ						
		 						
		 		-				
								
								_

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

Please type a plus sign (+) inside this box ->	+
loade type a place sign (· / IIISIGG GIIS DOX	_

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitut	e for form 1449	A/PTO			Complete if Known	
INIEC	DRAATI	ON DIS	CLOSURE	Application Number	09/194,356	
				Filing Date	September 2, 1999	
SIA	IEMEN	IBYA	PPLICANT	First Named Inventor	NERI et al.	
				Group Art Unit	1642	
	(use as man	y sheets as	necessary)	Examiner Name	A. M. Harris	
Sheet	2	of	2	Attorney Docket Number	NOTAR-2	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	001	ALAN L. EPSTEIN, et al.; Identification of a Monoclonal Antibody, TV-1, Directed against the Basement Membrane of Tumor Vessels, and Its Use to Enhance the Delivery of Macromolecules to Tumors after Conjugation with Interleukin 2 ¹ ; Cancer Research 55, 2673-2680, June 15, 1995	
·			
-			_
			_

Examiner	Date	 	
Signature	Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.